Results 21 to 30 of about 52,122 (312)

Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015–2018: a repeated cross-sectional analysis

BMJ Open, 2021
Objective To describe opioid agonist treatment prescribing rates in provincial prisons and compare with community prescribing rates.Design We used quarterly, cross-sectional data on the number and proportion of people prescribed opioid agonist treatment ...
Fiona Kouyoumdjian, Lori Kiefer, Susan Bondy, Claire Bodkin, Leonora Regenstreif   +4 more
doaj   +1 more source

BUPRENORPHINE IN OPIOID ADDICTION TEREATMENT: STUDIES WITH METHADONE COMPARISON

Psychiatry and Clinical Psychopharmacology, 2021
Methadone maintenance treatment is the most widely used pharmacological treatment approach for opioid addiction in many countries. In spite of many benefits that was gained after the usage of full agonist methadone, especially high numbers of patients ...
E.Cüneyt Evren, Defne Tamar, Bilge Babayağmur, Duran Çakmak   +3 more
doaj  

Mortality during opioid agonist treatment in Norway: A comprehensive study of the years 2014 and 2015

, 2022
Although opioid agonist treatment (OAT) substantially reduces morbidity and mortality in individuals with opioid dependence, mortality is still higher than in the general population.
Bech, Anne Berit
core   +1 more source

Evaluating comparative effectiveness of psychosocial interventions for persons receiving opioid agonist therapy for opioid use disorder: protocol for a systematic review

BMJ Open, 2018
Introduction The opioid crisis has resulted in increasing rates of death caused by problematic opioid use. Current clinical guidelines recommend that individuals with persons with opioid use disorder (OUD) receive pharmacological (eg, opioid agonist ...
Brian Hutton, Beverley Shea, Kimberly Corace, David Moher, Danielle B Rice, Becky Skidmore, Kednapa Thavorn, Sheena Taha, Dianna Wolfe, Fatemeh Yazdi, Beth A Sproule, Melanie Willows, Patricia Poulin, Gary Garber, Amy Porath, Leila Esmaeilisaraji   +15 more
doaj   +1 more source

Interim opioid agonist treatment for opioid addiction: a systematic review [PDF]

Harm Reduction Journal, 2022
Abstract Background Opioid use disorder is a public health problem and treatment variability, coverage and accessibility poses some challenges. The study’s objective is to review the impact of interim opioid agonist treatment (OAT), a short-term approach for patients awaiting standard OAT, in terms of treatment retention,
Laura Samsó Jofra, Teresa Puig, Ivan Solà, Joan Trujols   +3 more
openaire   +4 more sources

A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data

Harm Reduction Journal, 2020
Background Due to the high prevalence of mental disorders among people with opioid use disorder, the objective of this study was to determine the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention ...
Kristen A. Morin, Joseph K. Eibl, Graham Gauthier, Brian Rush, Christopher Mushquash, Nancy E. Lightfoot, David C. Marsh   +6 more
doaj   +1 more source

Ligand-Free Signaling of G-Protein-Coupled Receptors: Physiology, Pharmacology, and Genetics

Molecules, 2023
G-protein-coupled receptors (GPCRs) are ubiquitous sensors and regulators of cellular functions. Each GPCR exists in complex aggregates with multiple resting and active conformations. Designed to detect weak stimuli, GPCRs can also activate spontaneously,
Wolfgang Sadee
doaj   +1 more source

Corrigendum: Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system

, 2023
The authors wish to make the following corrections to their article: Mannaioni G, Lugoboni F. Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on ...
Fabio Lugoboni, Guido Mannaioni
core   +1 more source

Human Mas-related G protein-coupled receptors-X1 induce chemokine receptor 2 expression in rat dorsal root ganglia neurons and release of chemokine ligand 2 from the human LAD-2 mast cell line [PDF]

, 2013
Primate-specific Mas-related G protein-coupled receptors-X1 (MRGPR-X1) are highly enriched in dorsal root ganglia (DRG) neurons and induce acute pain. Herein, we analyzed effects of MRGPR-X1 on serum response factors (SRF) or nuclear factors of activated
Kathrin Rothe (386395), Ingrid Boekhoff, Ingrid Boekhoff (180345), Andreas Breit (180329), Solinski Hans Jürgen, Petermann, Franziska, Andreas Breit, Hans Jürgen Solinski (166922), Rothe Kathrin, Thomas Gudermann, Franziska Petermann, Boekhoff, Ingrid, Breit, Andreas, Boekhoff Ingrid, Rothe, Kathrin, Gudermann, Thomas, Gudermann Thomas, Breit Andreas, Thomas Gudermann (77426), Hans Jürgen Solinski, Petermann Franziska, Franziska Petermann (220017), Solinski, Hans Jürgen, Kathrin Rothe   +23 more
core   +1 more source

Substances used and OAT (Opioid agonist therapy).

, 2022
Substances used and OAT (Opioid agonist therapy).
Mitchell Levine (445928), Sarah van Gaalen (12436936), Dale Kalina (12436933), Aidan Reid Findlater (12436939), Mark Loeb (248712), Elizabeth Alvarez (4908070), Marek Smieja (117473), Sureka Pavalagantharajah (12436924), Anna Cvetkovic (10670541), Jacqueline Lim (4238824), Eric Lentz (12436930), Lawrence Mbuagbaw (117465), Carol Bassim (12436942), Cynthia Lokker (3813832), Jean-Eric Tarride (201689), Tim O’Shea (8283081), Chris P Verschoor (12436927), Robin Lennox (8314125)   +17 more
core   +1 more source